Comparable stake leader
Janus Henderson Group Ltd.
SEC ownership of MADRIGAL PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001157601.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- MDGL on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Janus Henderson Group Ltd.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001157601
- Issuer location
- West Conshohocken, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of MADRIGAL PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 8.8%
13D/G row: Janus Henderson Group Ltd.
Showing 1-8 of 50 holder rows.
Quick read
Janus Henderson Group Ltd. leads the comparable SEC ownership view at 8.8%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Janus Henderson Group Ltd.
8.8%
Paul A. Friedman
7.8%
Rebecca Taub
7.8%
PAULSON & CO. INC.
6.1%
BlackRock, Inc.
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
8.8%
|
$1,077,715,260
2,018,647 shares
|
+$231,599,280 | 31 Mar 2026 |
| Paul A. Friedman |
13D/G
3/4/5
Paul A Friedman, M.D. · Director
|
7.8%
|
$982,730,986
1,814,831 shares
|
$0 | 10 Dec 2025 |
| Rebecca Taub |
13D/G
3/4/5
Rebecca Taub, M.D. · Director
|
7.8%
|
$982,730,986
1,814,831 shares
|
$0 | 10 Dec 2025 |
| PAULSON & CO. INC. |
13D/G
13F
Company
|
6.1%
|
$743,261,329
1,392,188 shares
|
-$168,350,516 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
4.6%
from 13D/G
|
$644,753,455
1,200,770 shares
|
— | 30 Jun 2026 |
| Kenneth Bate |
3/4/5
Director
|
0.01%
|
$1,289,808
2,627 shares
|
-$8,027,354 | 05 Nov 2025 |
| BAKER BROS. ADVISORS LP |
13F
3/4/5
Company · Director
|
9.2%
|
$1,150,754,190
2,143,131 shares
|
— | 30 Jun 2026 |
| RTW INVESTMENTS, LP |
13F
Company
|
8.6%
|
$1,070,510,235
1,993,687 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$78,485,089.
Buys
$0
Insiders: 0
Sells
$78,485,089
Insiders: 9
Net
-$78,485,089
Shares: -150,679
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 150,679
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 4,206 | $0 | $2,226,755 | -$2,226,755 |
| 3-6 | 0 | 12,624 | $0 | $5,990,398 | -$5,990,398 |
| 6-9 | 0 | 99,537 | $0 | $53,485,657 | -$53,485,657 |
| 9-12 | 0 | 34,312 | $0 | $16,782,279 | -$16,782,279 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 29 reporting-owner rows connected to MADRIGAL PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
29
Largest Forms 3/4/5 holder
Felix Baker
Net 12M change
-$78,485,089
Latest report
17 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Felix Baker | Director | $1,020,178,119 | Mixed | 17 Jun 2026 | ||
| BAKER BROS. ADVISORS LP | Director | $1,020,178,119 | Mixed | 17 Jun 2026 | ||
| Julian C. Baker | Director | $1,020,178,119 | Mixed | 17 Jun 2026 | ||
| 667, L.P. | Director | $1,020,178,119 | Mixed | 17 Jun 2026 | ||
| Baker Bros. Advisors (GP) LLC | Director | $1,020,178,119 | Mixed | 17 Jun 2026 | ||
| Baker Brothers Life Sciences LP | Director | $1,020,178,119 | Mixed | 17 Jun 2026 | ||
| Rebecca Taub | Director | $580,113,117 | -$21,675,987 | -3.6% | Mixed | 17 Jun 2026 |
| Paul A. Friedman | Director | $484,919,577 | -$26,657,462 | -5.2% | Mixed | 09 Jan 2026 |
| Fred B. Craves | Director | $122,538,572 | Mixed | 12 Mar 2025 | ||
| William John Sibold | President and CEO, Director | $116,188,061 | -$7,487,673 | -6.1% | Filing P/S | 17 Jul 2026 |
| Richard S. Levy | Director | $11,761,847 | -$7,356,914 | -38% | Mixed | 17 Jun 2026 |
| Kelley Shannon T. | General Counsel | $5,908,765 | -$841,612 | -12% | Filing P/S | 17 Aug 2026 |
| Alex G. Howarth | Chief Financial Officer | $5,741,877 | Mixed | 23 Jan 2024 | ||
| Carole Huntsman | Chief Commercial Officer | $5,482,182 | -$1,713,308 | -24% | Filing P/S | 04 Mar 2026 |
| Mardi Dier | EVP and CFO | $5,466,248 | -$3,772,798 | -41% | Filing P/S | 04 Mar 2026 |
| Brian J. Lynch | SVP and General Counsel | $5,332,092 | Mixed | 23 Jan 2024 | ||
| David Soergel | Chief Medical Officer | $4,973,759 | -$951,981 | -16% | Filing P/S | 01 Jun 2026 |
| Remy Sukhija | Chief Commercial Officer | $3,659,044 | Mixed | 16 Jan 2023 | ||
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | $1,995,798 | Mixed | 05 Mar 2025 | ||
| James M. Daly | Director | $1,612,811 | Mixed | 17 Jun 2026 |
Recent insider transactions for MADRIGAL PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kelley Shannon T. | MDGL | Common Stock | Sale | -5.47% | $341,940 | $514.97 | -664 | 11,474 | 17 Aug 2026 | Direct |
| John C. Reed | MDGL | Common Stock | Award | 647 | 647 | 15 Aug 2026 | Direct | |||
| John C. Reed | MDGL | Stock Option (Right to Buy) | Award | 1,078 | 1,078 | 15 Aug 2026 | Direct | |||
| William John Sibold | MDGL | Common Stock | Sale | -1.18% | $1,368,253 | $547.30 | -2,500 | 209,329 | 20 Jul 2026 | Direct |
| William John Sibold | MDGL | Common Stock | Options Exercise | 30.9% | 50,000 | 211,829 | 17 Jul 2026 | Direct | ||
| William John Sibold | MDGL | Performance Restricted Stock Units | Options Exercise | -100% | -50,000 | 0 | 17 Jul 2026 | Direct | ||
| Rebecca Taub | MDGL | Common Stock | Award | 0.1% | 454 | 452,667 | 17 Jun 2026 | Direct | ||
| Rebecca Taub | MDGL | Stock Option (Right to Buy) | Award | 766 | 766 | 17 Jun 2026 | Direct | |||
| Richard S. Levy | MDGL | Common Stock | Award | 2.06% | 454 | 22,469 | 17 Jun 2026 | Direct | ||
| Richard S. Levy | MDGL | Stock Option (Right to Buy) | Award | 766 | 766 | 17 Jun 2026 | Direct | |||
| Jacqualyn A. Fouse | MDGL | Common Stock | Award | 41.4% | 454 | 1,551 | 17 Jun 2026 | Direct | ||
| Jacqualyn A. Fouse | MDGL | Stock Option (Right to Buy) | Award | 766 | 766 | 17 Jun 2026 | Direct | |||
| James M. Daly | MDGL | Common Stock | Award | 17.3% | 454 | 3,081 | 17 Jun 2026 | Direct | ||
| James M. Daly | MDGL | Stock Option (Right to Buy) | Award | 766 | 766 | 17 Jun 2026 | Direct | |||
| Daniel J. Brennan | MDGL | Common Stock | Award | 41.8% | 404 | 1,371 | 17 Jun 2026 | Direct | ||
| Daniel J. Brennan | MDGL | Stock Option (Right to Buy) | Award | 681 | 681 | 17 Jun 2026 | Direct | |||
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| Baker Bros. Advisors Lp | MDGL | Common Stock | Award | 0.09% | 1,816 | 1,948,876 | 17 Jun 2026 | See Footnotes | ||
| BAKER BROS. ADVISORS LP | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| BAKER BROS. ADVISORS LP | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| Baker Bros. Advisors Lp | MDGL | Non-Qualified Stock Options (right to buy) | Award | 3,064 | 1,532 | 17 Jun 2026 | See Footnotes | |||
| David Soergel | MDGL | Common Stock | Sale | -9.41% | $516,561 | $495.74 | -1,042 | 10,033 | 01 Jun 2026 | Direct |
| Richard S. Levy | MDGL | Common Stock | Sale | -20.5% | $2,928,716 | $515.44 | -5,682 | 22,015 | 22 May 2026 | Direct |
| David Soergel | MDGL | Common Stock | Sale | -7.08% | $435,420 | $515.90 | -844 | 11,075 | 18 May 2026 | Direct |
| Mardi Dier | MDGL | Common Stock | Sale | -13.7% | $853,993 | $430.87 | -1,982 | 12,490 | 06 Mar 2026 | Direct |
| William John Sibold | MDGL | Common Stock | Sale | -1.02% | $718,316 | $431.94 | -1,663 | 161,829 | 06 Mar 2026 | Direct |
| Kelley Shannon T. | MDGL | Common Stock | Sale | -2.88% | $155,498 | $431.94 | -360 | 12,138 | 06 Mar 2026 | Direct |
| Carole Huntsman | MDGL | Common Stock | Sale | -3.2% | $180,983 | $431.94 | -419 | 12,692 | 06 Mar 2026 | Direct |
| Rebecca Taub | MDGL | Common Stock | Sale | -0.11% | $212,083 | $431.94 | -491 | 452,213 | 06 Mar 2026 | Direct |
| Mardi Dier | MDGL | Common Stock | Award | 56.3% | 5,215 | 14,472 | 04 Mar 2026 | Direct | ||
| Mardi Dier | MDGL | Stock Option (Right to Buy) | Award | 6,519 | 6,519 | 04 Mar 2026 | Direct | |||
| William John Sibold | MDGL | Common Stock | Award | 10.1% | 14,995 | 163,492 | 04 Mar 2026 | Direct | ||
| William John Sibold | MDGL | Stock Option (Right to Buy) | Award | 18,743 | 18,743 | 04 Mar 2026 | Direct | |||
| Kelley Shannon T. | MDGL | Common Stock | Award | 47.4% | 4,017 | 12,498 | 04 Mar 2026 | Direct | ||
| Kelley Shannon T. | MDGL | Stock Option (Right to Buy) | Award | 5,022 | 5,022 | 04 Mar 2026 | Direct | |||
| Carole Huntsman | MDGL | Common Stock | Award | 43.7% | 3,989 | 13,111 | 04 Mar 2026 | Direct | ||
| Carole Huntsman | MDGL | Stock Option (Right to Buy) | Award | 4,986 | 4,986 | 04 Mar 2026 | Direct | |||
| David Soergel | MDGL | Common Stock | Award | 58% | 4,374 | 11,919 | 04 Mar 2026 | Direct | ||
| David Soergel | MDGL | Stock Option (Right to Buy) | Award | 5,467 | 5,467 | 04 Mar 2026 | Direct | |||
| Mardi Dier | MDGL | Common Stock | Sale | -11.3% | $505,389 | $427.21 | -1,183 | 9,257 | 02 Mar 2026 | Direct |
| Richard S. Levy | MDGL | Common Stock | Options Exercise | 9.92% | 2,500 | 27,697 | 23 Feb 2026 | Direct | ||
| Richard S. Levy | MDGL | Stock Option (Right to Buy) | Options Exercise | -100% | -2,500 | 0 | 23 Feb 2026 | Direct | ||
| Richard S. Levy | MDGL | Common Stock | Options Exercise | 18.9% | 4,000 | 25,197 | 26 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.